Medical Condition News

RSS

ADHD medication improves childhood cancer survivors: Research

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators.

14 Sep 2010

Neural inhibition critical in ability to make choices

A new University of Colorado at Boulder study sheds light on the brain mechanisms that allow us to make choices and ultimately could be helpful in improving treatments for the millions of people who suffer from the effects of anxiety disorders.

14 Sep 2010

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program). The grant will fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease known to cause blindness at an early age.

14 Sep 2010

Repetitive transcranial magnetic stimulation helps to regain motor function in partially paralyzed patients

Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.

14 Sep 2010

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.

14 Sep 2010

Potassium salt intake can improve blood pressure: Study

An increased intake of 'good' potassium salts could contribute significantly to improving blood pressure at the population level. The favourable effect brought about by potassium is even estimated to be comparable with the blood pressure reduction achievable by halving the intake of 'bad' sodium salts (mostly from table salt).

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C).

14 Sep 2010

Arthritis Foundation, Takeda launch Gout Living educational campaign

The Arthritis Foundation and Takeda Pharmaceuticals North America, Inc., announced the launch of a new educational campaign, Gout Living, to help increase understanding and encourage better management of gout.

14 Sep 2010

Myopia and Glaucoma genes identified

In global studies of more than 40,000 people from countries around the world, including Australia, researchers have found the genes responsible for two of the most common eye disorders - short-sightedness or myopia and glaucoma. The scientists believe this could open new diagnostic and management options.

13 Sep 2010

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

13 Sep 2010

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo.

13 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Ticagrelor exhibits potential for prevention of heart attacks

New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks.

13 Sep 2010

Defibtech receives Health Canada approval for Lifeline View AED device

Defibtech, LLC, a leading innovator in the Automated External Defibrillation (AED) market, today announced that it has received approval from Health Canada to market the Lifeline View™ AED device. The Lifeline View AED is the first and only AED to offer a full-color interactive display that shows users step-by-step how to perform CPR and external defibrillation.

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

American Cancer Society announces details of new campaign

The American Cancer Society, the official sponsor of birthdays, today announced details of a unique new campaign that marks the next phase of the Society's movement for More Birthdays. Over the past several months, dozens of the biggest names in music and art have come together, inspired by the efforts of the American Cancer Society, its supporters and everyone affected by cancer, to generously donate their talent and artwork to help amplify the voice of the More Birthdays movement.

13 Sep 2010

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Shire, the global specialty biopharmaceutical company, announces that the United States Food and Drug Administration today posted an update on its website related to ProAmatine (known generically as midodrine), a medicine approved for the treatment of symptomatic orthostatic hypotension.

13 Sep 2010

Medical Condition News

ADHD medication improves childhood cancer survivors: Research

Neural inhibition critical in ability to make choices

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Repetitive transcranial magnetic stimulation helps to regain motor function in partially paralyzed patients

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

Potassium salt intake can improve blood pressure: Study

Study finds new therapeutic target for polycystic kidney disease

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

Arthritis Foundation, Takeda launch Gout Living educational campaign

Myopia and Glaucoma genes identified

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Ticagrelor exhibits potential for prevention of heart attacks

Defibtech receives Health Canada approval for Lifeline View AED device

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

American Cancer Society announces details of new campaign

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News